PL2908912T3 - Szeroko neutralizujące przeciwciała anty-hiv - Google Patents

Szeroko neutralizujące przeciwciała anty-hiv

Info

Publication number
PL2908912T3
PL2908912T3 PL13847347T PL13847347T PL2908912T3 PL 2908912 T3 PL2908912 T3 PL 2908912T3 PL 13847347 T PL13847347 T PL 13847347T PL 13847347 T PL13847347 T PL 13847347T PL 2908912 T3 PL2908912 T3 PL 2908912T3
Authority
PL
Poland
Prior art keywords
neutralizing anti
hiv antibodies
widely neutralizing
widely
hiv
Prior art date
Application number
PL13847347T
Other languages
English (en)
Polish (pl)
Inventor
Hugo MOUQUET
Michel Nussenzweig
Pamela J. Bjorkman
Louise Scharf
Original Assignee
The Rockefeller University
California Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Rockefeller University, California Institute Of Technology filed Critical The Rockefeller University
Publication of PL2908912T3 publication Critical patent/PL2908912T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13847347T 2012-10-18 2013-10-18 Szeroko neutralizujące przeciwciała anty-hiv PL2908912T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715642P 2012-10-18 2012-10-18
PCT/US2013/065696 WO2014063059A1 (en) 2012-10-18 2013-10-18 Broadly-neutralizing anti-hiv antibodies
EP13847347.5A EP2908912B1 (en) 2012-10-18 2013-10-18 Broadly-neutralizing anti-hiv antibodies

Publications (1)

Publication Number Publication Date
PL2908912T3 true PL2908912T3 (pl) 2021-05-17

Family

ID=50488789

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13847347T PL2908912T3 (pl) 2012-10-18 2013-10-18 Szeroko neutralizujące przeciwciała anty-hiv

Country Status (20)

Country Link
US (6) US10047146B2 (enExample)
EP (2) EP3783018A1 (enExample)
JP (7) JP6461804B2 (enExample)
CN (3) CN118955699A (enExample)
AU (4) AU2013331049B2 (enExample)
BR (1) BR112015008635B1 (enExample)
CA (2) CA3236192A1 (enExample)
CY (1) CY1124405T1 (enExample)
DK (1) DK2908912T3 (enExample)
EA (2) EA201992107A1 (enExample)
ES (1) ES2822135T3 (enExample)
HR (1) HRP20201505T1 (enExample)
HU (1) HUE051577T2 (enExample)
IL (5) IL301018B2 (enExample)
LT (1) LT2908912T (enExample)
MX (2) MX376969B (enExample)
PL (1) PL2908912T3 (enExample)
PT (1) PT2908912T (enExample)
SI (1) SI2908912T1 (enExample)
WO (1) WO2014063059A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN112225798B (zh) * 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
PT2908912T (pt) * 2012-10-18 2020-09-04 Univ Rockefeller Anticorpos anti-hiv amplamente neutralizantes
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
WO2014134547A1 (en) * 2013-02-28 2014-09-04 Therabiol, Inc. Hiv antigens and antibodies
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
SI3166607T1 (sl) * 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
WO2016149698A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies)
ES2768957T3 (es) 2015-09-24 2020-06-24 Abvitro Llc Composiciones de anticuerpos contra el VIH y métodos de uso
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
WO2018075564A1 (en) 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
BR112019013468A8 (pt) * 2016-12-27 2022-11-22 Univ Rockefeller Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CN111971299A (zh) * 2018-02-21 2020-11-20 美国政府(由卫生和人类服务部的部长所代表) HIV-1 Env的中和抗体及其用途
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
IL317993B2 (en) 2018-07-03 2025-11-01 Gilead Sciences Inc Antibodies directed against HIV gp120 and methods of use
WO2020023827A1 (en) * 2018-07-27 2020-01-30 International Aids Vaccine Initiative Engineered antibodies to hiv env
US12441782B2 (en) 2018-09-14 2025-10-14 The Rockefeller University Anti-HIV antibody 10-1074 variants
MX428176B (es) * 2019-01-28 2025-11-13 Xyphos Biosciences Inc Ligandos nkg2d no naturales modificados que entregan selectivamente moléculas heterólogas unidas a receptores nkg2d no naturales en células car.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP3947445A1 (en) * 2019-04-04 2022-02-09 Vanderbilt University Hiv/hcv cross-reactive antibodies and uses thereof
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN112759651B (zh) * 2019-11-01 2022-09-20 北京华夏清医治疗科技有限公司 一种包含嵌合抗原受体修饰的t细胞及其应用
EP3831848A1 (en) * 2019-12-02 2021-06-09 Universität zu Köln Broadly neutralizing antibodies against hiv
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
EP4153181B1 (en) 2020-05-21 2026-07-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
LT4192474T (lt) 2020-08-07 2025-11-25 Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas
JP7518286B2 (ja) 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022403012B2 (en) 2021-12-03 2026-02-12 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
FI4440702T3 (fi) 2021-12-03 2025-08-08 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
AU2022399845B2 (en) 2021-12-03 2026-03-26 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
IL313306A (en) 2021-12-17 2024-08-01 Viiv Healthcare Co Combined treatments for HIV infections and their uses
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
CN119768183A (zh) 2022-08-26 2025-04-04 吉利德科学公司 用于广泛中和抗体的给药和安排方案
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
EP4698174A1 (en) 2023-04-19 2026-02-25 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
WO2024249573A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
CN122295099A (zh) 2023-07-28 2026-06-26 吉利德科学公司 用于治疗和预防hiv的来那卡帕韦的每周方案
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025050404A1 (zh) * 2023-09-08 2025-03-13 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物及其应用
KR20260093341A (ko) 2023-10-11 2026-06-19 길리애드 사이언시즈, 인코포레이티드 가교 트리시클릭 카르바모일피리돈 화합물 및 이의 용도
IL327206A (en) 2023-10-11 2026-05-01 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their uses
AU2024360779A1 (en) 2023-10-11 2026-04-16 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2026076265A1 (en) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors
WO2026117540A1 (en) 2024-11-27 2026-06-04 Vir Biotechnology, Inc. Anti-hiv-1 antibodies and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US81A (en) 1836-11-15 Erawijjg
US6593A (en) 1849-07-17 Cutting
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5798251A (en) * 1990-05-29 1998-08-25 Cedars-Sinai Medical Center Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
EP1373318A2 (en) 2001-01-26 2004-01-02 Abgenix, Inc. Neutralizing human monoclonal antibodies against hiv-1, their production and uses
CA2485120C (en) * 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1613953A4 (en) * 2003-04-14 2006-09-06 Children S Nat Medical Ct Inc ANTIRETROVIRAL ANALYSIS BY MASS SPECTROMETRY
US7667006B2 (en) * 2003-12-16 2010-02-23 Kumamoto Technology And Industry Foundation Anti-HIV antibody
US8268982B2 (en) * 2004-01-07 2012-09-18 Hitachi Chemical Co., Ltd. Primers and probes for the detection of HIV
JP4895727B2 (ja) * 2006-08-28 2012-03-14 シスメックス株式会社 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法
US20080279879A1 (en) * 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
EP2178560A2 (en) * 2007-07-23 2010-04-28 Maxygen, Inc. Chimeric hiv antigens
US20110262924A1 (en) * 2008-12-19 2011-10-27 Abbott Laboratories Molecular assay for diagnosis of hiv tropism
US20110212106A1 (en) * 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
RU2535034C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
CA3201524C (en) * 2010-08-31 2026-01-13 International Aids Vaccine Initiative Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2012074863A2 (en) * 2010-12-01 2012-06-07 Albert Einstein College Of Medicine Of Yeshiva University Constructs and methods to identify antibodies that target glycans
PT2908912T (pt) * 2012-10-18 2020-09-04 Univ Rockefeller Anticorpos anti-hiv amplamente neutralizantes

Also Published As

Publication number Publication date
WO2014063059A1 (en) 2014-04-24
ES2822135T3 (es) 2021-04-29
US10392433B2 (en) 2019-08-27
IL301018B1 (en) 2025-11-01
CA2888659C (en) 2024-06-04
IL238320A0 (en) 2015-06-30
IL285049A (en) 2021-08-31
CN112920269A (zh) 2021-06-08
AU2019201039B2 (en) 2020-08-27
IL293362B1 (en) 2023-04-01
AU2023201926B2 (en) 2025-08-14
IL301018A (en) 2023-05-01
CA3236192A1 (en) 2014-04-24
US11142564B2 (en) 2021-10-12
AU2013331049A1 (en) 2015-04-16
BR112015008635A2 (pt) 2018-09-04
JP2025118727A (ja) 2025-08-13
JP6732872B2 (ja) 2020-07-29
US10047146B2 (en) 2018-08-14
PT2908912T (pt) 2020-09-04
US20190345233A1 (en) 2019-11-14
JP2024010023A (ja) 2024-01-23
EA201992107A1 (ru) 2020-04-30
JP2022115946A (ja) 2022-08-09
CA2888659A1 (en) 2014-04-24
MX2015004924A (es) 2015-10-29
HUE051577T2 (hu) 2021-03-01
CN118955699A (zh) 2024-11-15
IL301018B2 (en) 2026-03-01
JP2026126317A (ja) 2026-08-04
EP2908912B1 (en) 2020-08-05
AU2019201039A1 (en) 2019-03-07
MX376969B (es) 2025-03-07
EA035012B1 (ru) 2020-04-17
CN104918658B (zh) 2021-02-19
US20180282400A1 (en) 2018-10-04
AU2020244391B2 (en) 2023-02-16
US11649276B2 (en) 2023-05-16
CY1124405T1 (el) 2022-03-24
AU2020244391A1 (en) 2020-10-29
US20250320280A1 (en) 2025-10-16
IL323371A (en) 2025-11-01
US20150274813A1 (en) 2015-10-01
EP2908912A1 (en) 2015-08-26
HRP20201505T1 (hr) 2020-12-11
EP3783018A1 (en) 2021-02-24
US20220002390A1 (en) 2022-01-06
BR112015008635B1 (pt) 2023-10-31
US20230279082A1 (en) 2023-09-07
JP7376898B2 (ja) 2023-11-09
EA201590741A1 (ru) 2015-09-30
CN104918658A (zh) 2015-09-16
IL293362B2 (en) 2023-08-01
JP2019071888A (ja) 2019-05-16
MX2020011669A (es) 2021-02-15
EP2908912A4 (en) 2016-05-25
JP2015534982A (ja) 2015-12-07
US12338277B2 (en) 2025-06-24
JP7863842B2 (ja) 2026-05-22
JP2021003104A (ja) 2021-01-14
JP7076722B2 (ja) 2022-05-30
HK1212935A1 (en) 2016-06-24
IL293362A (en) 2022-07-01
AU2013331049B2 (en) 2018-11-15
CN112920269B (zh) 2024-05-24
LT2908912T (lt) 2020-09-25
IL285049B (en) 2022-07-01
AU2023201926A1 (en) 2023-05-04
IL238320B (en) 2021-08-31
DK2908912T3 (da) 2020-10-26
JP7681278B2 (ja) 2025-05-22
SI2908912T1 (sl) 2021-03-31
JP6461804B2 (ja) 2019-01-30

Similar Documents

Publication Publication Date Title
CY2024011I1 (el) Αντισωματα anti-fcrn
IL293362A (en) Broadly-neutralizing anti-hiv antibodies
SMT201600476B (it) Tenofovir alafenammide emifumarato
DK2934584T3 (da) Anti-gdf15-antistoffer
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
PT2858671T (pt) Formulação de anticorpos
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
DK3117837T3 (da) Antistofformuleringer
HRP20181874T1 (hr) Anti-cxcr3 protutijela
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
PT2931313T (pt) Formulações de solução de anticorpos anti-il-23p19 modificados
DK3431504T3 (da) Antiphospholipase d4-antistof
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
DK2828292T3 (da) Jcv-neutraliserende antistoffer
EP2832221A4 (en) HUMANIZED MOUSE
DK2935330T3 (da) Anti-notch3-antistoffer
EP2814843A4 (en) IL-BETA NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
UA25626S (uk) Печиво
DK2828284T3 (da) Jcv-neutraliserende antistoffer
DE112013004839A5 (de) Antriebsstrang
IL237613A0 (en) Methods for identifying hiv neutralizing antibodies
UA25859S (uk) Піца
UA23735S (uk) Печиво
UA24443S (uk) Упаковка для круасану